Navigation Links
Popular cancer drug can cause kidney damage
Date:6/10/2010

The widely used cancer drug bevacizumab may cause severe loss of protein from the kidney into the urine that can lead to significant kidney damage and can compromise the efficacy of cancer treatment, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). The results suggest that physicians should monitor patients' kidney health when prescribing this angiogenesis inhibitor.

While research indicates that treatment with the chemotherapy drug bevacizumab can lead to urinary protein leakage (proteinuria) and kidney damage, the overall risk associated with the drug and patient risk factors are unknown. Bevacizumab blocks a protein called vascular endothelial growth factor, thus inhibiting the production of new blood vessels around tumors.

Shenhong Wu MD, PhD (Stony Brook University Cancer Center), Xiaolei Zhu, MD, PhD (Kidney Doctors PLLC), and their colleagues conducted a review of published randomized, controlled clinical trials to assess the overall risk for severe proteinuria in patients taking bevacizumab. The researchers analyzed data from 16 studies comprising 12,268 patients with a variety of tumors.

Severe proteinuria occurred in 2.2% of patients taking bevacizumab. Compared with patients taking chemotherapy alone, patients taking bevacizumab combined with chemotherapy had a 4.79-fold increased risk of developing severe proteinuria and a 7.78-fold increased risk of developing nephrotic syndrome. (Nephrotic syndrome is a group of symptoms including protein in the urine, low blood protein levels, high cholesterol levels, high triglyceride levels, and swelling.)

Patients taking higher dosages of bevacizumab had the greatest risk of developing proteinuria. Also, when the investigators looked at differences by cancer type, they found that patients with kidney cancer had the highest risk of developing proteinuria (10.2% incidence).

These results indicate that it is particularly important to monitor the effects of bevacizumab in patients who have kidney cancer or who are receiving high doses of the drug. Future studies should investigate how to reduce bevacizumab's kidney-related effects, and physicians should be prepared to treat these potential side effects.


'/>"/>

Contact: Shari Leventhal
sleventhal@asn-online.org
202-416-0658
American Society of Nephrology
Source:Eurekalert

Related medicine news :

1. Wii Popularity Leads to New Kind of Gaming Injury
2. Presidents As Popular as a Root Canal Comment Misses Mark
3. Religion a Popular Topic of Discussion Among US Physicians on Sermo
4. Urinary Incontinence Rates Increase Worldwide As Awareness Grows About Treatment Options: Urethral Slings Are Popular Alternatives When Medications Fail
5. Dr. Michael Aziz Releases a New Nutrition Book That Debunks Most Popular Diets and Diet Books
6. Chicago Plastic Surgeon Discusses the Popularity and Safety of Silicone Breast Implants Three Years after FDA Approval
7. Psychology Popular Among College Students
8. Is a Tummy Tuck Right for Me? Alabama Plastic Surgeon Dr. David Durst Offers Tips as the Popularity of Surgical Cosmetic Enhancement Continues to Rise
9. Americans Remain Split on Stalled Health Care Legislation, but Some Provisions Popular Among Majorities of Democrats, Independents and Republicans
10. Popular Diet Plans Can Unclog Arteries
11. Popular nanoparticle causes toxicity in fish, study shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... While it’s often important ... problem. Fortunately, an inventor from Austin, Texas, has identified a solution. , She developed ... darkness or restricted lighting. As such, it eliminates the need to turn on a ...
(Date:10/13/2017)... Vegas, Nevada (PRWEB) , ... October 13, 2017 , ... ... 7® Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD ... dose required and providing a CBD form that can be easily incorporated into liquid ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton Lakes , which specializes ... of the facility as part of a disaster drill on October 3rd. , Apple ... Shelton City Emergency Manager, as well as the Connecticut Long Term Care Mutual ...
(Date:10/13/2017)... NY (PRWEB) , ... October 13, 2017 , ... Ellevate ... people in business to advocate for action towards gender equality at their inaugural Summit ... from around the globe, and reached a social audience of over 3 million. To ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented ... the lowdown on sciatica in a new episode of "Success Files," which is ... events and innovation and investigates each subject in-depth with passion and integrity. , ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
(Date:9/28/2017)... 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), will ... and webcast on Friday, November 3, 2017, beginning at ... at approximately 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... financial performance and guidance for 2018, Hill-Rom executives will ... operational performance, and long-range financial outlook through 2020. ...
(Date:9/25/2017)... , Sept. 25, 2017   Montrium , ... File solutions, today—from the IQPC Trial Master Files ... , NL)—announced that EastHORN Clinical Services has selected ... programs and TMF management. EastHORN, a leading European ... platform to increase transparency to enable greater collaboration ...
Breaking Medicine Technology: